ESMO Guidelines: Real World Cases - Webinar Series: Renal Cell Carcinoma 2025

Description

This ESMO Clinical Practice Guidelines Webinar focused on renal cell carcinoma and its application in a real-world case.

Metastatic renal cell carcinoma (mRCC) remains a critical focus in oncology due to its significant global incidence, accounting for 80% of kidney cancers and constituting 5% of adult malignancies in men and 3% in women. As of 2024, the management of mRCC has advanced significantly, particularly with the integration of novel immunotherapies and targeted treatments, as reflected in the updated ESMO clinical practice guidelines. These developments highlight the complexity of treatment sequencing and the necessity for clinicians to stay informed about the latest evidence-based recommendations. Given the rapid pace of therapeutic advancements and the geographical variability in disease incidence, a webinar on the 2024 guidelines would provide a timely opportunity to disseminate critical information, address practical challenges, and discuss real-world applications. Such an initiative is essential for optimising clinical decision-making and improving patient outcomes in mRCC management.